Departamento de Áreas Acadêmicas, Instituto Federal de Educação, Ciência e Tecnologia de Goiás, Campus Goiânia Oeste, Goiânia, GO, Brasil.
Instituto Federal de Educação, Ciência e Tecnologia de Goiás, Campus Valparaíso, Valparaíso, GO, Brasil.
Braz J Med Biol Res. 2021 Dec 10;55:e11631. doi: 10.1590/1414-431X2021e11631. eCollection 2021.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused several problems in healthcare systems around the world, as to date, there is no effective and specific treatment against all forms of COVID-19. Currently, drugs with therapeutic potential are being tested, including antiviral, anti-inflammatory, anti-malarial, immunotherapy, and antibiotics. Although antibiotics have no direct effect on viral infections, they are often used against secondary bacterial infections, or even as empiric treatment to reduce viral load, infection, and replication of coronaviruses. However, there are many concerns about this therapeutic approach as it may accelerate and/or increase the long-term rates of antimicrobial resistance (AMR). We focused this overview on exploring candidate drugs for COVID-19 therapy, including antibiotics, considering the lack of specific treatment and that it is unclear whether the widespread use of antibiotics in the treatment of COVID-19 has implications for the emergence and transmission of multidrug-resistant bacteria.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染在全球医疗体系中引发了诸多问题,因为迄今为止,尚无针对所有形式的 COVID-19 的有效且特效的治疗方法。目前正在测试具有治疗潜力的药物,包括抗病毒药、抗炎药、抗疟药、免疫疗法和抗生素。尽管抗生素对病毒感染没有直接作用,但它们常被用于治疗继发性细菌感染,甚至作为经验性治疗以降低病毒载量、感染和冠状病毒的复制。然而,这种治疗方法存在诸多顾虑,因为它可能会加速和/或增加长期抗生素耐药性(AMR)的发生率。我们专注于探索 COVID-19 治疗的候选药物,包括抗生素,因为目前缺乏特效治疗方法,而且尚不清楚在 COVID-19 治疗中广泛使用抗生素是否会对多药耐药菌的出现和传播产生影响。